Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-921: pembrolizumab plus docetaxel and prednisone versus placebo plus docetaxel and prednisone in chemotherapy-naive metastatic castration-resistant prostate cancer
MOH_2019-03-25_006029Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Pembrolizumab + docetaxel + prednisone/prednisolone with Placebo + docetaxel + prednisone/prednisolone (2 arms). Started Mar 2019; status: completed.
02
Drugs
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on MOH_2019-03-25_006029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-03-25_006029.